IBN SINA Pharma's profit growth takes a pause in FY23

The profit of IBN SINA Pharmaceutical Industry remained almost unchanged for FY23 as it recorded no notable rise in revenue compared to the previous fiscal year.
Its consolidated profit was Tk 605.50 million in FY23, which was Tk 605.81 million in the previous fiscal year.
Company secretary Md. Kabir Hossain said the company's revenue was also almost constant for the years.
A slow and steady growth in the company's profit had been observed for the previous three fiscal years.
The profit was Tk 336.27 million for FY19, Tk 392.53 million for FY20 and Tk 489.12 million for FY21.
The company's consolidated earnings per share (EPS) stood at Tk 19.38 for FY23, reduced slightly from Tk 19.39 for FY22.
Meanwhile, the company's board of directors recommended 60 per cent cash dividend for FY23.
It distributed 60 per cent cash dividend for FY22, 47 per cent for FY21 and 38 per cent for FY20.
The company's share price had frequent ups and downs between Tk 286.6 and Tk 289.6 in April.
Later, the stock remained stuck at the floor price of Tk 286.6 between May 3 and July 7.
Having seen a marginal appreciation on July 23, the stock again fell to the floor. The stock had no movement on Tuesday.
Sponsor-directors of the 'A' category company hold 44.67 per cent shares, institutes 24.34 per cent and general investors 30.99 per cent, according to the data available until the end of July.

mufazzal.fe@gmail.com